CS Pharmaceuticals Announces the appointment of Andrew Wilks to its Board of Directors

CS Pharmaceuticals Ltd (“CSP” or “the Company”), a specialty pharmaceutical company focussed on the in-license of China rights of innovative products and the development and commercialisation of them in China , today announces that Andrew Wilks has been appointed as a Non-Executive Director.  Andrew is Founder and Executive Chairman of SYNthesis med Chem, CEO of Catalyst Therapeutics and Co-Founder of Qubist Molecular Design and an Honorary Professor at the University of Melbourne.  At SYNthesis Andrew built and subsequently sold a large business based in Shanghai.   Andrew has over 100 peer reviewed publications, in excess of 70 US patents and patent applications and work that has been cited more than 12,500 times in the scientific literature.

Steven Harris, CSP’s Chairman, said:

“We are delighted to welcome Andrew to CSP.  The combination of his development expertise and his experience of building a successful business in China will be extremely valuable to CSP as the Company licenses, develops and commercialises western medicines in China”